A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine
Short Description
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Release Date
May 23, 2017

This 7-day double-blind, parallel-group, placebo-controlled inpatient study will compare the effects of 15 mg of intravenous methamphetamine given 60 hours before and 12 hours after a single oral dose of reserpine (0.5 or 1.0 mg) or placebo.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. PleaseĀ contact us for assistance.

Study Data
Study Links
Study Documents
Case Report Form(s)
Deidentification Notes
Nulled Values
All Documents